Reines 1992

Methods	n = 49 Allocation concealment: not described Baseline similarity: not described Blinding: caregivers Cointerventions: not described Withdrawals: not described Losses to follow‐up: not described
Participants	Inclusion: Sepsis‐induced ARDS Exclusions: Not described
Interventions	Continuously aerosolized synthetic surfactant (Exosurf) with DPPC 40.5 mg/ml, or with DPPC 81 mg/ml, or placebo (nebulized 0.6% saline), for up to 5 days
Outcomes	14 day mortality (all surfactant doses versus control): RR 0.61 (95% CI 0.30 to 1.24) Adverse events leading to discontinuation of therapy not reported Other safety information: treatment: 2/33 patients had exhalation filter occlusion
Notes	Published only as abstract
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Unclear risk	B ‐ Unclear